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Cancer is a major cause of death in the world. Cancer affected 
12.7 and 14.1 million people, in 2008 and 2012, with a 
mortality rate of 7.6 and 8.2 million people, respectively.[1,2] In 
Iran, cancer is the third leading cause of death and its reported 
incidence rate in men and women is 98 and 110 cases per 
100,000 people, respectively. The reported cancer-induced 
death is 41 and 65 deaths per 100,000 people among 
men and women, respectively.[3] During the course of the 
disease and treatment of cancer, patients experience several 
complications, the most common of which are pain (80%), 
fatigue (90%), weight loss (80%), appetite loss (80%), 
nausea (90%), anxiety (25%), shortness of breath (50%), 
and dizziness (80%).[4] The manifestation of these symptoms 
impairs patients’ quality of life and functionality and can 
interrupt the process of treatment and reduce the effectiveness 
of treatment protocols.[5]
Given that many of the annoying symptoms in cancer patients 
are subjective, it is difficult for nurses to assess and control 
them. This reveals the importance of having a standard tool 
that can identify both objective and subjective problems of 
patients for nurses.[6] Numerous questionnaires have been 
developed to evaluate physical signs as well as cognitive and 
mental performance in cancer patients.[7-12] One of such tools 
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is the Edmonton Symptom Assessment Scale (ESAS). It was 
first designed by Bruera et al. in 1991 to evaluate common 
problems among patients with cancer.[9] Each ESAS item is 
scored from 0 to 10. The total symptom distress score ranges 
from 0 to 100.[13] Due to its ease of use, ESAS was quickly 
used in palliative care and care programs for cancer patients 
and was adopted by different researchers in Spain, Italy, 
Thailand, Germany, Switzerland and China.[13-18] Dong et al. 
for instance evaluated the psychometric properties of ESAS in 
China and approved its criterion validity, internal consistency, 
and reliability.[18]
One of the issues that have been less addressed in previous 
studies is the factor structure of ESAS. Although Bruera 
et al. introduced a one-dimensional structure (total symptom 
distress score) for ESAS, Carvajal et al. through exploratory 
factor analysis suggested that a reasonable structure for 
ESAS is a three-dimensional including soft physical 
symptoms (nausea, appetite, drowsiness, weakness), emotional 
components (anxiety, depression, a feeling of well-being, 
and difficulty in sleeping), and hard physical symptoms 
(pain and difficulty in breathing).[13] Several studies have 
evaluated the psychometric properties of ESAS, but they did 
not address its factor structure. [9,14-16,19] This is while further 
studies appear necessary to examine the factor structure of 
ESAS.
Palliative care has recently started in Iran,[20] and no studies 
have yet been conducted to standardize a proper assessment 
system to assess the cancer patients’ symptoms in Iran. 
ESAS is simple and comprehensive compared to other tools 
and can be easily completed by patients and also easily 
interpreted; hence, it can be used in care centers for cancer 
patients in Iran, provided that its psychometric properties 
are approved. Therefore, the present study was conducted 
to determine the psychometric properties of ESAS in Iran 
and also to examine its factor structure in one-dimensional[9] 
and three-dimensional models according to the dimensions 
suggested by Carvajal et al.[13]
Materials and Methods
This methodological study was conducted to translate and 
validate ESAS in cancer patients in the Oncology-Hematology 
wards and Chemotherapy Clinics of Imam Khomeini Hospital 
in Ardabil, Iran. The inclusion criteria were aged over 18 years, 
the ability to communicate verbally and consent to participate 
in the study. The exclusion criteria were excessive fatigue, 
psychological diseases (according to the patient’s history and 
medical records), and the inability to answer the questions.
After obtaining permission from the ESAS designers, the tool 
was translated to Persian by two English experts separately 
and then compared and corrected to prepare a final version; 
then, it was retranslated to English. The content and face 
validity (content validity index [CVI]), discriminant validity, 
criterion validity, and construct validity (confirmatory factor 
analysis [CFA] and discriminant validity using statistical 
analysis), internal consistency, and stability reliability were 
used to assess the psychometrics of the tool. The CVI was 
used to determine content validity of the tool according to 
the views of 13 professors and experts after the translation of 
ESAS, where the CVI for relevance, simplicity, and clarity of 
the Persian version of ESAS was 100%, 100%, and 92.3%, 
respectively.
After a face-to-face discussion and briefing the subjects 
about the objectives and method of the study, their consent 
was obtained, and the questionnaire was read and completed 
by the researcher for them. ESAS was used in the nine items 
introduced by Bruera et al.,[9] and the tenth item was blank 
and filled according to the other problems that patients have 
experienced.
To determine discriminant validity according to the patient’s 
general condition (Karnofsky Performance Scale), the patients 
were divided into two groups of critically ill patients and patients 
with a good general condition, and ESAS was completed for 
each group separately. Finally, the discriminative validity was 
determined by comparing the scores of the two groups. The 
Functional Assessment of Cancer Therapy-General (FACT-G) 
was used as a standard tool to determine criterion validity. The 
tool was used by Rezaei et al. in 2011 in Iran and its content 
validity and internal consistency were approved.[21] Various 
studies have approved the validity of FACT-G as standard 
criteria for evaluating ESAS.[10,16,22]
The CFA of ESAS was used to evaluate its factor structure 
in two models. In the first model, ESAS was considered a 
single-factor scale with nine items as introduced by Bruera 
et al.[9] In the second model, based on the model introduced by 
Carvajal et al.,[13] ESAS was considered a three-dimensional 
scale including soft physical symptoms (nausea, appetite, 
drowsiness, weakness), emotional components (anxiety, 
depression, a feeling of well-being, and difficulty in 
sleeping), and hard physical symptoms (pain and difficulty 
in breathing). Since a small number of patients mentioned 
other symptoms (tenth item), the “difficulty in sleeping” 
item was not examined in this study. In the next step, 
discriminant validity of the three-dimensional model was 
calculated using statistical tests for further analysis of the 
construct validity. To determine the discriminant validity at 
this point, it was assumed that despite the correlation of the 
three factors (dimensions) of the tools, each factor should 
be separated from other factors so that two or three of them 
are not considered one factor. For this purpose, the average 
variance extracted (AVE) was compared to the square of the 
correlation between factors. Discriminant validity is confirmed 
when the square of correlations between factors is less than 
every single average variance extracted.[23-26]
The Cronbach’s alpha coefficient was used to evaluate the 
reliability of internal consistency and to evaluate the stability 
reliability, a retest was taken from 242 patients within 3–6 h, 
and the correlations between the two tests were calculated. The 
CFA was conducted using the LISREL software version 8.8 
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and other analyses were performed using  SPSS for Windows, 
Version 15.0 (SPSS Inc., Chicago, Illinois, USA).
results
Data were collected during 6 months from oncology centers 
and clinics of Imam Khomeini Hospital in Ardabil, Iran. 
A total number of 260 eligible patients were enrolled. Among 
them, 14 patients were excluded because of unwillingness 
to answer all items. Totally, data from 246 patients were 
analyzed, among whom 120 patients were admitted to 
hematology-oncology ward and 126 were outpatients in the 
chemotherapy and radiotherapy clinic. Their mean age was 
55.19 ± 14.11 years, ranging from 19 to 84 years. Among the 
subjects, 137 were men (55.7%), 205 were married (83.3%), 
126 were illiterate (51.2%), 102 were homemaker (41.5%), 
154 had gastrointestinal cancer (62.6%), and <6 months has 
passed since the diagnosis in 137 patients (55.7%).
The discriminant validity of the tool was studied by comparing the 
scores of ESAS in two groups of critically ill patients and patients 
with a good general condition. Since the scores of ESAS and 
all items were significantly higher in the group of patients with 
a good general condition compared to the critically ill patients, 
the discriminant validity of the tool was confirmed [Table 1].
The FACT-G was used as a standard tool to determine 
the criterion validity. The Spearman’s Rho test showed a 
high and inverse correlation between ESAS and FACT-G 
(r = −0.74, P < 0.001). Since higher scores in FACT-G indicate 
better performances and also lower scores in ESAS indicate 
less distress in patients; thus, the inverse correlation between 
these two tools can approve the criterion validity of ESAS. 
A relatively high and inverse correlation was also found 
between ESAS and physical well-being (r = −0.81, P < 0.001), 
emotional well-being (r = −0.39, P < 0.001), and functional 
well-being (r = −0.53, P < 0.001), while there was no 
significant relationship between ESAS and family/social 
well-being dimension (r = −0.08, P = 0.2) in FACT-G.
The construct validity was determined using CFA to evaluate 
factor structure of the tool in two models: single factor 
and three factor. The Chi-square/df in the single-factor 
and three-factor model was 4.25 and 3.14, respectively. 
According to coefficients of other goodness of fit indices 
[Table 2 and Figures 1, 2], the goodness of fit was confirmed 
in both single-factor and three-factor models. As shown in 
Table 3, the AVE (diagonal value in bold) of each construct 
is less than the square of correlation coefficients between 
the respective constructs. It shows that the three dimensions 
of ESAS are highly correlated with one another and their 
discriminant validity cannot be statistically confirmed.
The correlation among nine items was analyzed to determine the 
internal consistency. The total alpha coefficient of the scale was 
Table 1: The discriminant validity of the Edmonton Symptom Assessment Scale by comparing the scores of Edmonton 
Symptom Assessment Scale in two groups of critically ill patients and patients with a good general condition
ESAS Critically ill patients (n=142) Patients with a good general condition (n=104) Mann–Whitney U‑test (P)
Pain 5.84±2.82 4.60±2.88 0.001
Weakness 6.90±2.06 5.40±2.76 <0.001
Nausea 2.87±2.60 2.69±2.97 0.30
Depression 6.62±2.02 5.32±2.95 0.001
Anxiety 6.10±2.87 4.38±3.26 <0.001
Drowsiness 6.30±2.22 5.28±2.95 0.007
Appetite 5.59±2.75 3.72±2.80 <0.001
Feeling of well-being 6.65±1.74 5.10±2.64 <0.001
Difficulty in breathing 2.62±2.99 1.60±2.5 0.002
ESAS total score 49.49±14.99 38.08±18.62 <0.001
The score of ESAS and all items are different in two groups of patients. ESAS: Edmonton Symptom Assessment Scale
Figure 1: Standardized parameter estimates for Model I (one‑factor 
Edmonton Symptom Assessment Scale). Weak: Weakness, Naus: Nausea, 
Drows: Drowsiness, Appet: Appetite, Dep: Depression, Anx: Anxiety, 
WellB: Feeling of well‑being, DBreath: Difficulty in breathing
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α = 0.88. In addition, the Cronbach’s alpha coefficient during 
the assessment of the internal consistency for the dimensions 
of soft physical symptoms, emotional components, and hard 
physical symptoms was 0.74, 0.78, and 0.57, respectively. The 
correlation between the two administrations of the test with a 
3–6 h interval in 242 samples was 0.86 (P < 0.0001, r = 0.86). 
Assessing the correlation between ESAS dimensions in the 
test and retest showed that the highest correlation pertained to 
the loss of appetite (r = 0.85) and the lowest correlation to the 
feeling of well-being (r = 0.66) and the correlation coefficients 
of other items were between the two values (r = 0.73–0.82).
disCussion and ConClusions
Checking the symptoms of cancer patients is a key element of 
palliative care. Since ESAS is a simple comprehensive tool 
that easily specifies acute problems of the patients, the present 
study was conducted to evaluate the psychometric properties 
and factor structure of ESAS in patients with cancer. The results 
of this study showed that the Iranian version of ESAS had a 
good reliability and validity.
The discriminant validity of ESAS is approved because it had 
a significantly higher score in critically ill patients compared 
to the patients with a good general condition (P < 0.001). 
Previous studies have also reported good discriminant validity 
for ESAS. Carvajal et al. for instance divided patients into 
three groups using Karnofsky Performance Scale and found an 
inverse correlation between Karnofsky score and ESAS items, 
i.e., an increase in Karnofsky score (improvement in patient 
performance) decreased ESAS score. They also showed that 
admitted patients had higher ESAS scores than outpatients, 
which further approve the discriminant validity of ESAS.[13] 
Chang et al. (2000) also found an inverse correlation between 
Karnofsky score (as a better performance measure in patients) 
and all ESAS items.[10] Although the total score and the scores 
of ESAS dimensions were different in the two groups of 
patients, nausea did not show a significant difference. It appears 
that nausea, regardless of the patient’s general condition, was 
more or less present in all patients and is not a good measure 
to discriminate between people with good and bad general 
conditions. Carvajal et al. observed no significant difference in 
nausea score between the two groups of good and bad general 
conditions, either.[13]
Based on the high correlation of ESAS and FACT-G, its 
criterion validity was confirmed. It was also found that ESAS 
was highly correlated with FACT-G dimensions including 
physical well-being, emotional well-being, and functional 
well-being, while there was no relationship between ESAS and 
the family/social well-being dimension. The poor relationship 
between ESAS and the family/social well-being in the 
FACT-G was expected because ESAS items include physical 
and psychological symptoms but not family or social items. 
Previous studies in this field have approved criterion validity 
of ESAS, too.[10,13,19] For example, Chang et al. examined 
the criterion validity and found a relatively high correlation 
between ESAS and FACT-G (r = −0.69).[10] Furthermore, 
Yeşİlbalkan et al. used Rotterdom Symptom Checklist (RSCL) 
Table 2: Goodness of fit indices of single‑factor and 
three‑factor models of Edmonton Symptom Assessment 
Scale
Models χ2 df NFI NNFI CFI IFI GFI SRMR
Single factor 114/85 27 0/95 0/94 0/96 0/96 0/91 0.049
Three factor 75/49 24 0/96 0/96 0/97 0/97 0/94 0.043
df: Degree freedom, NNFI: Nonnormed fit index, IFI: Incremental fit index, 
GFI: Goodness of fit index, SRMR: Standardized root-mean-square residual, 
CFI: Comparative fit index
















R2=1.00, P<0.001* R2=0.81, P<0.001* 0.44
Diagonal values in bold indicating average variance extracted of the each 
construct
Figure 2: Standardized parameter estimates for Model II (three‑factor 
Edmonton Symptom Assessment Scale). Sof t: Sof t Physical 
Symptoms, Emotion: Emotional Components, Hard: Hard Physical 
Symptoms Weak: Weakness, Naus: Nausea, Drows: Drowsiness, 
Appet: Appetite, Dep: Depression, Anx: Anxiety, WellB: Feeling of 
well‑being, DBreath: Difficulty in breathing
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to evaluate criterion validity and found a high correlation 
between ESAS and RSCL scores (r = 0.75).[19]
The assessment of factor structure of ESAS confirmed original 
ESAS introduced by Bruera et al. in the form of nine items and 
one dimension.[9] Previous studies examining the psychometrics 
of ESAS also confirmed the one-dimensional model.[10,13,14,16,18] 
However, despite the confirming psychometric properties 
of ESAS, Carvajal et al. used exploratory factor analysis in 
examining the factor structure of the tool and achieved three 
dimensions of soft physical, hard physical, and emotional 
components,[13] which was different from the one-dimensional 
factor structure introduced by Bruera et al. The present study 
performed CFA and discriminant validity using SEM to 
confirm or reject the three-dimensional factor structure of 
ESAS introduced by Carvajal et al.[13] Although the goodness of 
fit indices of the three-factor structure of ESAS was approved, 
the high correlation between the dimensions indicates that 
three dimensions of ESAS overlap to the extent that they 
cannot be differentiated as separate dimensions. The approved 
one-dimensional factor structure is also another proof of the 
rejection of the multidimensionality of ESAS. Meanwhile, 
it was expected that if multidimensionality of ESAS was 
proved, the single-factor model was rejected because in such 
conditions, the tool is potentially made of more than one 
factor.[23-25] In addition, the higher Cronbach’s alpha coefficients 
for single-factor structure (α = 0.88) compared with the 
three-factor model (α = 0.57–0.78) show that the single-factor 
structure of ESAS is preferred to the three-factor structure.
The test-retest method indicated a good reliability for ESAS. 
Previous studies have shown contradictory results in terms 
of its reliability, which might be due to the differences in the 
interval between the two tests. For example, Chang et al. (2000) 
conducted a study in the US to examine the reliability and 
validity of ESAS and examined the test-retest in two intervals. 
Their results showed that the retest had a high correlation with 
the test after 1 day, while it reduced significantly with a 1-week 
interval.[10] One of the problems of retesting is that the two tests 
might not have the same conditions. Since ESAS examines 
symptoms that are mostly physical, the shorter time between 
the two tests will lead to a higher correlation. For example, 
in the study of Carvajal et al., performing the test-retest with 
4–6 h intervals, the results indicated a very high correlation 
between the two tests.[13] All in all, according to the results of 
this study and previous studies,[10,16,17,19,27] it appears that ESAS 
has an acceptable reliability.
This study showed that based on content, criterion, and 
discriminant validities and stability and internal consistency of 
the Persian version of ESAS, the tool can be used to measure 
the distressing symptoms of cancer patients in Iran. The 
results of this study can be a cornerstone to further studies 
in this field and also a step toward the widespread use of this 
valuable tool at all medical, rehabilitation, and palliative care 
centers for cancer patients. One of the features of this study was 
investigating the factor structure of the tool in two models (one 
factor and three factor). Although ESAS classification in three 
dimensions of soft physical, emotional, and hard physical can 
be more effective in planning and performing nursing care, the 
results showed that ESAS is more acceptable under the total 
symptom distress score, and in all patients (patients with good 
general and critically ill conditions), all nine items emerge or 
disappear together.
One of the limitations of the study was using FACT-G for 
criterion validity assessment. Although the tool is used in Iran 
and its content validity and internal consistency are approved,[21] 
it is not completely localized in accordance with the standards 
of psychometrics in Iran and should be cautiously used as 
a criterion. ESAS can be used by both the assessor and the 
patient, but it was only completed by researchers in the present 
study; therefore, it is suggested that in the future studies, the 
tool be completed by patients, too. Another limitation of this 
study was conducting the research among cancer patients in 
Ardabil which makes the generalization of the results more 
difficult. It is recommended that the psychometric properties 
of the tool be assessed in other parts of Iran, too.
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